Fig. 10

Characterization of the tumor microenvironment (TME) molecular features in patients with varying PTGES3 expression levels. (A) Analysis of the association between immune signaling pathways and patient survival rates, utilizing the IOBR package for evaluation. (B) Comparison of the top 20 immune signaling pathways between patients with high and low PTGES3 expression. (C) Representation of inhibitory signaling distribution in patients with high versus low PTGES3 expression. (D) Representation of immune rejection signaling distribution in patients with high versus low PTGES3 expression. (E) Profiling of immune cell abundance in patients with high and low PTGES3 expression, employing the CIBERSORT deconvolution method. *p < 0.05; **p < 0.01; ***p < 0.001; NS denotes not statistically significant.